Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (9179)	3/10/2002 9:18:46 AM
From: aknahow	Respond to of 9719

Who was the head of the FDA ten years ago? A new head can be named at once if that person is on record as being in favor of greater control over the evil drug companies. What is happening is exposing to more eyes what is perhaps wrong with the system. So while it is pinful in the short run it may be beneficial in the longer run.

To: Rocketman who wrote (9179)	3/10/2002 10:58:05 AM
From: ewolf	Respond to of 9719

Vector clearly hasn't lost touch. Sepracor type setbacks happen all the time. Flumist approval is very interesting. They were taken down three times? Does Avalon have a sell out on medi? Perhaps the outcome on Flumist will be a good indicator on the outcome of Soltara since the safety issues raised are in the same territory. And of course, there's always Corixa? Whether its Coulter or Corixa, the company keeps being blamed for some kind of incompetence beacause the drug's efficacy seems so clear. I wonder if the company understands fully what the fda wants to see. In the end, some element of the approval process seems to be arbitrary, a fine line of judgement as to whether a drug should be available or not. So much data, so easy to find an objectionable aspect. It makes the process unpredictable. Successful investing includes luck. Vector has simply hit a bad patch. That will change.